

DAFTAR PUSTAKA

1. Pellegriti G, Frasca F, Regalbuto C, Squatrito S, Vigneri R. Worldwide Increasing Incidence of Thyroid Cancer : Update on Epidemiology and Risk Factors. *Journal of Cancer Epidemiology*. 2013: 1-11.
2. Khan A. *Surgical Pathology of Endocrine and Neuroendocrine Tumors*. Humana Press; 2009:41-80.
3. Sung H, Ferlay J, Siegel RL, *et al*. Global Cancer Statistics 2020 : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. 2021;71(3):209-249. doi:10.3322/caac.21660
4. Sun J hung, Li Y rong, Chang K hsuan, Liou M jene. Evaluation of recurrence risk in patients with papillary thyroid cancer through tumor-node- metastasis staging : A single-center observational study in Taiwan. *Biomed J*. 2021;45(6):923-930. doi:10.1016/j.bj.2021.11.009.
5. Badan Registrasi Kanker Perhimpunan Dokter Spesialis Patologi Indonesia 2014. *Kanker di Indonesia tahun 2014 : Data Histopatologik*. 2014. Jakarta Direktorat Jendral Pelayanan Medik Kementerian Kesehatan RI, Yayasan Kanker Indonesia, Jakarta
6. Araque KA, Gubbi S, Klubo-gwiezdzinska J, Branch D, Diseases K. Updates on the Management of Thyroid Cancer. *Horm Metab Res*. 2020;52(8):562-577. doi:10.1055/a-1089-7870.Updates.
7. Fahey TJ. Updates in the Understanding and Management of Thyroid Cancer. *Intechopen*.2012:165-188.
8. Rosai J, Albores SJ, Asioli S, Baloch ZW, Bogdanova T, Chen H *et al*. Papillary thyroid carcinoma in : World Health Organization Classification of Tumours Pathology & Genetics Tumours of Endocrine Organs. Lyon. 2017: 81-10.
9. Rosai J, Talini G. Thyroid gland. In : Rosai and Ackerman's *Surgical Pathology*. Tenth Edition. New York. USA. Elsevier. 2011: 487-28.
10. Morais RM De, Sobrinho AB, Maria C, *et al*. Review Article The Role of the NIS (SLC5A5) Gene in Papillary Thyroid Cancer : A Systematic Review. *Journal of Cancer Epidemiology*.2018:1-11. doi.org/10.1155/2018/9128754
11. Du L, Zhao Z, Zheng R, Li H, Zhang S, Li R. Epidemiology of Thyroid Cancer : Incidence and Mortality in China. *Frontiers in Oncology* 2020;10.1-9. doi:10.3389/fonc.2020.01702.
12. Putri E, Khambri D, R Selvi R. Artikel Penelitian Hubungan Daerah Tempat Tinggal dengan Gambaran Histopatologi Karsinoma Tiroid pada Masyarakat

Sumatera Barat. Jurnal Kesehatan Andalas.2014;3(2):147-150.

13. Hunt L Jennifer . Molecular Pathology of Endocrine Disease. Springer; 2010: 27-36.
14. Lee SG, Kyung W, Doolittle L, Lee HS. Practical Performance of the 2015 American Thyroid. 2017;(January). doi:10.1089/thy.2016.0252.
15. Coca-pelaz A, Rodrigo JP, Shah JP, *et al.* Recurrent Differentiated Thyroid Cancer : The Current Treatment Options. Published online 2023.
16. Anekpuritanang T, Uataya M, Claimon A, Laokulrath N, Pongsapich W, Pithuksurachai P. The Association Between Radioiodine Refractory in Papillary Thyroid Carcinoma , Sodium / Iodide Symporter Expression , and BRAF V600E Mutation. Dovepress. 2021:3959-3969. doi : 10.2147/OTT.S308910
17. Carvalho p denise. ferreira c.f andrea.The Importance of Sodium/Iodide Symporter (NIS) for Thyroid Cancer Management. Arq Bras Endocrinol Metab. 2007;51(5) :672-682.
18. Feng F, Yehia L, Ni Y, Chang YS, Jhiang SM. A Nonpump Function of Sodium Iodide Symporter in Thyroid Cancer via Cross-talk with PTEN Signaling. Aacr journal. 2018.78(21):6121-6133. doi:10.1158/0008-5472.CAN-18-1954.
19. Morari EC, Marcello MA, Guilhen ACT, *et al.* Use of sodium iodide symporter expression in differentiated thyroid carcinomas. Clinical Endocrinology. 2011:247-254. doi:10.1111/j.1365-2265.2011.04032.x
20. Ravera S, Reyna-Neyra A, Ferrandino G, Amzel LM, Carrasco N. The Sodium/Iodide Symporter (NIS): Molecular Physiology and Preclinical and Clinical Applications. Annu Rev Physiol. 2017;79:261-289. doi:10.1146/annurev-physiol-022516-034125
21. Elliyanti A, Rustam R, Tofrizal T, Yenita Y, Susanto YDB. Evaluating the Natrium Iodide Symporter Expressions in Thyroid Tumors. Macedonian Journal of Medical Sciences. 2021;9:18-23.
22. Lee F, Kuo CY, Tsai CH, Cheng SP. Propensity Score-Matched Analysis to Identify Pathways Associated with Loss of Sodium Iodide Symporter in Papillary Thyroid Cancer. Curr Issues Mol Biol. 2022;44(4):1488-1496. doi:10.3390/cimb44040101.
23. Humprey Peter A, dehner Louis P, Pleifer John D. the Washington Manual of Surgical Pathology. Wolters Kluwer.; 2012: 404-426.
24. Drozd V, Branovan DI, Reiners C. Increasing Incidence of Thyroid Carcinoma : Risk Factors and Seeking Approaches for Primary Prevention. Int J Thyroidol. 2020;13(2):95-110.

25. Crnčić TB, Tomaš MI, Girotto N, Ivanković SG. Risk Factors for Thyroid Cancer : What Do We Know So Far ?. *Acta Clin Croat.* 2020;59:66-72. doi:10.20471/acc.2020.59.s1.08
26. Thomson LD, Wenig BM, Muller S, Nelson B. Papillary Thyroid Carcinoma. In : *Diagnostic Pathology Head and Neck.* 2th . Philadelphia. Elsevier. 2016.: 988-18.
27. Kumar V, Abbas AK, Aster JC. Endocrine System. In : *Robbin and Cottran :Pathologic Basic of Disease.* 9th Ed. Philadelphia : Elsevier Saunders. 2015: 715-50.
28. Marc Pusztaszeri MA. Update on the Cytologic Features of Papillary Thyroid Carcinoma Variants. *Wiley Online Libr.* 2017;0(0):245-251. doi:10.1002/dc
29. Almkhtar ZK. Histopathological Types Clinicopathologic Study of Papillary Thyroid Carcinoma. *Macedonian Journal of Medical Sciences.* 2022;10:79-83.
30. Mingzhao Xing. Molecular Pathogenesis of Thyroid cancer. *NIH public Access.*2013;13(3):184-199. doi:10.1038/nrc3431.Molecular
31. Thompson L. Update on follicular variant of papillary thyroid carcinoma with an emphasis on new terminology : noninvasive follicular thyroid neoplasm with papillary- like nuclear features. *Diagnostic Histopathol.* Elsevier. 2016:1-8. doi:10.1016/j.mpdhp.2016.04.009.
32. Sadow PM, Hunt JL. Update on clinically important variants of papillary thyroid carcinoma. *Diagnostic histopathology.* Elsevier. 2010:106-113.
33. Nose Vania. *Diagnostic Pathologi Endocrine.* Elsevier.2nd edition. Elsevier.2018:158-226.
34. Pisanu A, Deplano D, Reccia I, Porceddu G, Uccheddu A. Encapsulated papillary thyroid carcinoma : Is it a distinctive clinical entity with low-grade malignancy ? *J. Endocrinol.* 2013:78-83. doi:10.3275/8241.
35. Arrangoiz R, Llano JG De, Mijares MF, *et al.* Current Understanding of Papillary Thyroid Carcinoma. *International Journal of Otolaryngology and Head & Neck Surgerye.* 2021;10:184-221. doi:10.4236/ijohns.2021.103019.
36. La Rosa Stefano, Silvia Ucella. *Endocrine Pathology.*Springer.2022:709-715
37. Chereau N, Giudicelli X, Pattou F, *et al.* Diffuse Sclerosing Variant of Papillary Thyroid Histopathological Features and a Poor Outcome : Results of a Large Multicentric Study. *J Clin Endocrinol Metab.* 2016;101:4603-4610. doi:10.1210/jc.2016-2341.
38. Shah JP, Ronald JCH prera, Rodrigo JP, *et al.* Papillary Thyroid Cancer — Aggressive Variants and Impact on Management : A Narrative Review. *Adv Ther.* 2020:3112-3128. doi:10.1007/s12325-020-01391-1.

39. Livolsi VA. Papillary thyroid carcinoma : an update. *Mod Pathol.* 2011;1-9. doi:10.1038/modpathol.2010.129.
40. Asioli S, *et al.* Papillary Thyroid Carcinoma with Prominent Hobnail Features : A New Aggressive Variant of Moderately of Eight Cases. *Am J Surg Pathol.* 2010;34(1):44-52.
41. Spyroglou A, Kostopoulos G, Tseleni S, *et al.* Hobnail Papillary Thyroid Carcinoma, A Systematic Review and Meta-Analysis. *cancers mdpi.* 2022:1-13.
42. Lubitz CC, Economopoulos KP, Pawlak AC, *et al.* Hobnail Variant of Papillary Thyroid Carcinoma : An Institutional Case Series and Molecular Profile. 2014;24(6):958-965. doi:10.1089/thy.2013.0573
43. Parkhi M, Chatterjee D, Bardia A. Papillary thyroid carcinoma with nodular fasciitis-like stroma : a rare variant. *Autops Case Rep.* 2021:1-6.
44. Lloyd V ricardo. *Endocrine Pathology Differential Diagnose and Molecular Advances.* Springer. 2010:237-254
45. Ohashi R. Solid variant of papillary thyroid carcinoma : an under- recognized entity. *Endocrine Journal. Int J Clin Exp Pathol.* 2020;67(3):241-248.
46. Ma X, Xia C, Liu H, Zhu W. Case Report Primary thyroid spindle cell tumors : spindle cell variant of papillary thyroid carcinoma ? . *Int J Clin Exp Pathol .* 2015;8(10):13528-13531.
47. Juhlin CC. Clear Cell Variant of Papillary Thyroid Carcinoma With Associated Anaplastic Thyroid Carcinoma : Description of an Extraordinary Case. *International Journal of Surgical Pathology.* 2019. doi:10.1177/1066896919837678
48. Naser F, Saud K. Clear Cell Variant of Papillary Thyroid Carcinoma : A Case Report. *J Med Cases.* 2019;10(4):113-115
49. Roman SA, Sosa JA. Management of Thyroid Nodules and Differentiated Thyroid Cancer. *Springer.*2017:165-181.
50. Bilimoria KY, Bentrem DJ, Linn JG, *et al.* Utilization of total thyroidectomy for papillary thyroid cancer in the United States. *Surgery.* 2003:906-913. doi:10.1016/j.surg.2007.09.002
51. Barra MB. Variants of papillary thyroid carcinoma: association with histopathological prognostic factors. *Braz J Otorhinolaryngol.* 2013;79(6):738-744. doi:10.5935/1808-8694.20130135
52. Patel A, Jhiang S, Dogra S, *et al.* Sodium-Iodide Symporter Have a Lower Risk of Recurrence for Children and Adolescents. *Pediatric Research.* 2002;52(5):17-19. doi:10.1203/01.PDR.0000031920.28469.B8

53. Hingorani M, Spitzweg C, Vassaux G, *et al.* The Biology of the Sodium Iodide Symporter and its Potential for Targeted Gene Delivery. NIH Public Access. 2014;10(2):242-267.
54. Portulano C, Paroder-belenitsky M, Carrasco N. The Na⁺/I⁻ Symporter (NIS): Mechanism and Medical Impact. 106 *endo journals*. 2014;35:106-149. doi:10.1210/er.2012-1036
55. Micali S, Bulotta S, Puppini C, *et al.* Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer. Published online 2014:1-12.
56. Riesco-eizaguirre G, Santisteban P, Vieja A De. The complex regulation of NIS expression and activity in thyroid and extrathyroidal tissues. *BMC Cancer*. 2021;14(303):1-12.
57. Dayanand K, Olivia E. Atherton, Jennifer L. Tackett, Emilio Ferrer and RWR. Kcne2 Deletion Uncovers its Crucial Role in Thyroid Hormone Biosynthesis. *Physiol Behav*. 2018;176(5):139-148. doi:10.1038/nm.2029.Kcne2
58. Ryu K yul, Senokozlieff ME, Smanik PA, *et al.* Development of Reverse Transcription-Competitive Polymerase Chain Reaction Method to Quantitate the Expression Levels of Human Sodium Iodide Symporter. 1999;9(4):405-409.
59. Tavares C, Tavares C, Coelho MJ, Eloy C, Melo M, Gaspar A. NIS expression in thyroid tumors, relation with prognosis clinicopathological and molecular features. *Endocrine connections*. 2018;90:78-90.
60. Wolff AC, Hammond MEH, Hicks DG, *et al.* Recommendations for human epidermal growth factor receptor 2 testing in breast. *J Clin Oncol*. 2013;31(31):3997-4013. doi:10.1200/JCO.2013.50.9984.
61. Elmageed ZYA, Sholl AB, Tsumagari K. Immunohistochemistry as an accurate tool for evaluating BRAF-V600E mutation in 130 samples of papillary thyroid cancer. *Surgery*.:1-7. doi:10.1016/j.surg.2016.06.081
62. Griesinta Trianty Andria Pinahayu, Diah Prabawati Retnani KWA, Harun Al Rasyid HS. Hubungan Ekspresi her2 dengan Ukuran Tumor dan Invasi Kapsular Papillary Thyroid Carcinoma (PTC). *Maj Kesehatan*. 2021;8:20-31.
63. Cui Q, Wang K, Zhang D. The role of radioactive iodine therapy in papillary thyroid cancer: an observational study based on SEER. *Dovepress*. 2018:3551-3560.
64. Glenn D. Braunstein. *Thyroid Cancer*. 1st ed. Springer Berlin Heidelberg; 2012:133-154.
65. Harahap AS, Subekti I, Panigoro SS, *et al.* Profile of BRAFV600E, BRAFK601E, NRAS, HRAS, and KRAS Mutational Status, and

Clinicopathological Characteristics of Papillary Thyroid Carcinoma in Indonesian National Referral Hospital. *Appl Clin Genet.* 2023;99-110. doi:10.2147/TACG.S412364.

66. Fang Y, Zheng X, Zou X, *et al.* Genetic and clinical profiles of 160 papillary thyroid cancers with lateral neck lymph node metastasis. *Front Oncol.* 2023;12(January):1-8. doi:10.3389/fonc.2022.1057532
67. Jalali-Nadoushan MR, Amirtouri R, Davati A, Askari S, Siadati S. Expression of estrogen and progesterone receptors in papillary thyroid carcinoma. *Casp J Intern Med.* 2016;7(3):183-187.
68. Walczyk A, Pałyga I, Trybek T, *et al.* Is Male Sex A Prognostic Factor in Papillary Thyroid Cancer ?. *Journal of medical medicine.* 2021:1-13.
69. Rusmana MP, Sriwidayani NP, Mahendra Dewi IGAS. BRAF V600E expression found in aggressive papillary thyroid carcinoma (PTC), lymph node metastasis, and extra-thyroid extension. *Bali Med J.* 2018;7(3):658-662. doi:10.15562/bmj.v7i3.1201.
70. Bertol BC, Massaro JD, Debortoli G, *et al.* BRAF, TERT and HLA-G Status in the Papillary Thyroid Carcinoma: A Clinicopathological Association Study. *Int J Mol Sci.* 2023;24(15). doi:10.3390/ijms241512459.
71. Appetecchia M, Lauretta R, Barnabei A, *et al.* Papillary Thyroid Carcinomas (MTC / PTC): An Italian Multicenter Study. *Cancers.*2019 :1-12.
72. Teixeira E, Bella-cueto MR, Soares P. Clinicopathological Features as Prognostic Predictors of Poor Outcome in Papillary Thyroid Carcinoma. *Cancers.* 2020:1-16.
73. Wei S, Gao M, Zhao C. Low expression of sodium iodide symporter expression in aggressive variants of papillary thyroid carcinoma. *Int J clin oncol.*2013. doi:10.1007/s10147-013-0620-z.
74. Dong H, Shen W zhuang, Yan Y jing, Yi J lin, Zhang L. Effects of BRAF V600E Mutation on Na + / I - Symporter Expression in. *J Huazhong univ sci Technol.*2016;36(1). doi:10.1007/s11596-016-1545-3.
75. Zhang H, Chen D. Synergistic inhibition of MEK / ERK and BRAF V600E with PD98059 and PLX4032 induces sodium / iodide symporter (NIS) expression and radioiodine uptake in BRAF mutated papillary thyroid cancer cells. *Thyroid research.* .2018:1-6.
76. Ayd C, Ersoy R, Cakir B, Güler G. The correlation of sodium iodide symporter and BRAF V600E mutation in classical variant papillary thyroid carcinoma *Annals of Diagnostic Pathology Elsevier.* .2016;22:58-62. doi:10.1016/j.anndiagpath.2016.04.002.

77. Castro MR, Bergert ER, Goellner JR, *et al.* Immunohistochemical Analysis of Sodium Iodide Symporter Expression in Metastatic Differentiated Thyroid Cancer: Correlation with Radioiodine Uptake. *The Journal of clinical endocrinology and metabolism.*2001;86(11):5627-5632.
78. Ming J, Liu Z, Zeng W, *et al.* mutations , and RET rearrangements and the clinical features of papillary thyroid cancer. *Int J Clin Exp Pathol.* 2015;8(11):15155-15162.

